FDA Inspection 1161579 — Sumitomo Pharma America, Inc.
The FDA completed an inspection of Sumitomo Pharma America, Inc. on Nov 5, 2021 in Marlborough, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 5, 2021
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Marlborough, MA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)